The recent US Supreme Court decision in Loper Bright Enterprises v. Raimondo is poised to significantly impact the way cannabis companies approach their tax obligations, particularly concerning Section 471(c) of the Internal Revenue Code. With the elimination of Chevron deference, which had previously required courts to adhere closely to agency interpretations of ambiguous laws, cannabis firms now have a stronger basis for challenging IRS positions that may be deemed overly restrictive or unfair.
Section 280E of the Internal Revenue Code has long posed a substantial burden for cannabis businesses by disallowing deductions and credits for expenses related to the illegal sale of drugs. Consequently, many cannabis firms have had to add substantial expenses, such as rent and wages for sales staff, back into their federal tax calculations, resulting in elevated tax obligations. The only relief provided has been for expenditures that count toward the cost of goods sold. While some states have decoupled from this federal requirement, the majority of the tax burden remains at the federal level.
Section 471(c), introduced by the Tax Cuts and Jobs Act of 2017, offers a potential alleviation for small businesses with yearly gross receipts under $30 million as of 2024. This section allows qualifying businesses to treat inventory for tax purposes as they do in their financial statements, potentially enabling them to capitalize more overhead costs, thereby increasing the cost of goods sold and reducing their 280E tax burden. However, the IRS has previously issued regulations countering this approach, asserting that 471(c) does not permit deductions precluded under other sections of the tax code.
The Supreme Court’s decision in Loper Bright removes judicial deference to certain IRS interpretations, which experts believe may lead to an increase in legal challenges against some IRS regulations. This development could be particularly beneficial for cannabis companies, whose tax strategies often involve intricate and challenging interpretations of the tax code. Legal analysts suggest that while the decision may result in more litigation, it also offers a pathway for cannabis businesses to obtain more favorable rulings from tax courts regarding 471(c).
For cannabis companies and advisers keen on leveraging Section 471(c), it is imperative to ensure meticulous bookkeeping that accurately reflects the reallocation of expenditures into the cost of goods sold. Preparing for potential audits and being able to substantiate every claimed expense is essential. Moreover, the specifics of expense allocation should be closely coordinated between cannabis firms and their tax advisers to optimize the benefits of this tax code provision.
Beyond the immediate tax implications, the broader legal and regulatory landscape for cannabis is also evolving. The Drug Enforcement Administration’s recent move to begin the process of reclassifying cannabis to a less dangerous controlled substance could positively influence the tax status of cannabis businesses in the long term.
Although the Loper Bright decision does not directly address Section 471(c), its principles support clearer and fairer accounting practices for cannabis companies. As the legal environment continues to shift, consulting with tax professionals will be crucial for cannabis businesses seeking to navigate these changes effectively.
For further information, the detailed discussion by Abraham Finberg and Simon Menkes on this topic can be found on Bloomberg Tax.